Introduction
Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues (i.e. 90Y-DOTATOC, 177 Lu-DOTATATE) has been shown to be an effective tool in treating metastasized gut neuroendocrine tumors (NET) [1, 2] . These gut NET are characterized by the presence of a high number of somatostatin receptor subtype 2 (sst 2 ) that are distributed on the tumor cell membranes [3] , and are the molecular basis for therapy with somatostatin analogs. Tumoral sst 2 can be detected not only in vivo by an Octreoscan Ó [4] but also in vitro by receptor autoradiography [5] or recently by immunohistochemistry [6] .
In pituitary GH- [7] , TSH- [8, 9] and ACTH-secreting tumors [10] , PRRT with radiolabeled somatostatin analogs is rarely chosen. Instead, non-radioactive somatostatin analogues (octreotide, lanreotide) are established in inhibiting hormone secretion and-in part-growth of these tumors, the effectiveness of the therapy being dependent on the receptor expression. In non-functioning pituitary adenoma (NFPA), the therapy is primarily surgical rather than octreotide or PRRT, in particular since the somatostatin receptors of the sst 2 subtype are much less frequently expressed [3, 11, 12] . In pituitary NFPA with higher proliferation index (WHO II), a type of tumor which is often a therapeutical challenge, data on sst 2 status are virtually missing.
In this paper we report for the first time of a patient with a NFPA WHO II and severe ocular manifestations, who had a tumor with high density of sst 2 which could be brought under control for over 8 years, after a PRRT with radiolabeled somatostatin analogs was performed.
Case report
In 1996, a 56 years old patient was referred for brain MRI scan due to new severe right-sided headache. A pituitary macroadenoma with infiltration into the right cavernous sinus and extending to the optic chiasm was diagnosed. There was no visual field deficit at the time and the clinical and biochemical work up was consistent with a NFPA without pituitary deficiencies.
In October 1996 the patient underwent successful transsphenoidal surgery. Residual adenoma remained in the right cavernous sinus which was impossible to remove (Fig. 1a) . A fat pad was introduced between the intact pituitary gland on the left side and the right cavernous sinus. This allowed for protecting the functioning pituitary gland from the planned radiotherapy. Histologically, a null-cell adenoma with a high proliferation index was documented (MIB-1: 11.6 %) consistent with a pituitary adenoma WHO II. Additionally, at that early stage of disease, somatostatin receptor autoradiography ( 125 I-Tyr 3 -Octreotide) was performed that showed a homogenous expression of sst 2 receptors in high density in the adenoma ( Fig. 2A) .
In November 1996 radiosurgery was performed for the residual tumor using gamma knife (dose 50 Gy). No pituitary insufficiencies ensued and visual fields and opthalmological examination were normal.
Follow-up MRI scans in 1997 and 1999 showed stable residual adenoma, in 2001 even a reduction of the residual tumor was detected and the patient renounced further neuroradiological follow-up.
In 2004, the patient was investigated following an acute decrease in visual acuity with additional double images in the horizontal axis. In addition, incomplete ptosis of the right eyelid and right eye mydriasis was evident suggesting oculomotor nerve palsy (Fig. 3) . MRI scan demonstrated a significant increase in the volume of the adenoma in the (Fig. 1b) indicating that the opthalmological symptoms were related to a progression of the adenoma. A second surgical intervention was impossible and an additional radiotherapy carried a significant risk for side effects. Due to the known high expression of sst 2 in the adenoma the patient consented to an experimental therapy approach using PPRT with Lutetium DOTATOC andafter a positive Octreoscan TM (Fig. 2B) 
Discussion
To our knowledge this is the first case of a patient with a NFPA (WHO II) in whom PRRT successfully stabilized and improved the local complications of the tumor after ineffective surgery and gamma knife therapy. The determination of sst 2 in vitro using autoradiography and in vivo by Octreoscan was instrumental to administer this experimental therapy in a clinically challenging situation.
While the therapeutical effect of somatostatin analogues in controlling autonomous endocrine secretion and inducing GH-adenoma shrinking is well established [7, 9, 10, 13, 14] the effectiveness of somatostatin analogues on local tumor control in patients with NFPA, is less evident: not only is the sst 2 expression much lower than in other pituitary tumors [3, 11] but also the octreotide effect is much more difficult to assess due to the lack of a reliable hormonal parameter. Moreover, surgery and-if neededradiotherapy is usually capable to control the disease in the vast majority of patients. Several uncontrolled short-term studies (3-12 months) indicate that somatostatin analogues may stabilize residual tumor size in NFPA but do not induce significant tumor shrinkage [15] [16] [17] [18] . One recent prospective study over 3 years assessed the effect of octreotide LAR on progression in NFPA with postoperatively residual tumor and suggest an effect on stabilization but not on shrinkage [19] .
PRRT-a targeted radiotherapy-results in a stabilization of the disease with regard to secretion (if present) and growth [1, 2] in metastasized gut neuroendocrine tumors [1, 2] that are well known to contain sst 2 in high density. Because PRRT in these tumors is known to induce persisting side-effects (renal failure, bone marrow toxicity [2] ), the indication for therapy has to be carefully discussed on the basis of somatostatin receptor status. No PRRT study with long-term follow-up in NFPA has been published. Two recent communications reported the efficacy and safety of PRRT in a patient with pituitary metastasis of a NET [20] and in a patient with a giant prolactin secreting tumor resistant to dopamine-agonists [21] , but the follow-up of the two cases was less than 2 years and the somatostatin receptor profile had not been analyzed in vitro before therapy. The present tumor presented on one hand with a high density of sst 2 and, on histology, with an elevated mitotic index consisting with an atypical pituitary adenoma (WHO II). In the German pituitary registry atypical adenoma account for 2.7 % of all registered pituitary neoplasms and the null cell adenomas were amongst the most frequent type [22] . Some evidence suggests that atypical adenomas have a poorer prognosis that may be related to a higher degree of local invasiveness, larger size and accelerated growth as shown in the present case. In such challenging cases an additional therapeutical strategy based on targeted radiotherapy may be helpful in controlling the disease.
Personalized medicine is a new therapeutical strategy in oncology that considers molecular targets of the tumors into the treatment regime [23] . The present case may impressively support the concept that personalized medicine should be discussed in endocrine patients, at least in those who present with a challenging course of their disease such as NFPA (WHO II). A prerequisite is the availability of a simple way to reliably measure somatostatin receptors in vitro within the tumor sample in order to have a molecular rationale for PRRT. Eight years ago the rather complex and costly receptor autoradiography technique was used to analyze sst receptors in this patient because no satisfactory alternative existed. An sst 2 antibody has recently been developed that can, alternatively, be employed in future to detect sst 2 immunohistochemically on formalin-fixed tissue [6] . This will simplify the therapeutical strategy in challenging cases and may contribute to a personalized medicine in endocrinology.
